Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.31 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.31 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1946266 | 0.87 | ALDH1A1 (0.35) | GRM4ALDH1A1KDM4EGAAMAPT | |
| SCHEMBL1192406 | 0.87 | ALDH1A1 (0.35) | GRM4ALDH1A1KDM4EGAAMAPT | |
| SCHEMBL1947643 | 0.87 | ALDH1A1 (0.35) | GRM4ALDH1A1KDM4EGAAMAPT | |
| SCHEMBL1464425 | 0.87 | LMNA (0.37) | GRM4ALDH1A1KDM4EGAAMAPT | |
| SCHEMBL1191751 | 0.82 | CCNT1 (0.35) | GRM4MAPK1GRM2CCNT1CDK9 | |
| SCHEMBL1948934 | 0.82 | CCNT1 (0.35) | GRM4MAPK1GRM2CCNT1CDK9 | |
| SCHEMBL1948800 | 0.82 | CCNT1 (0.35) | GRM4MAPK1GRM2CCNT1CDK9 | |
| SCHEMBL1192484 | 0.81 | PSEN1 (0.35) | CNR2 | |
| SCHEMBL1192581 | 0.78 | CCNT1 (0.40) | GRM4CCNT1CDK9 | |
| SCHEMBL10179677 | 0.74 | GRM4 (0.37) | GRM4MAPK1GRM2CCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2459535-B1 | PYRIDINE AND PYRAZINE DERIVATIVES AS PROTEIN KINASE MODULATORS | NOVARTIS AG (CH) | 2015-03-25 | — | — | EP | disclosed |
| US-20140288076-A1 | HETEROARYL COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2014-09-25 | — | — | US | disclosed |
| US-8778951-B2 | Heteroaryl compounds and their uses | NOVARTIS AG (CH) | 2014-07-15 | — | — | US | disclosed |
| EP-2668162-A1 | SUBSTITUTED BI-HETEROARYL COMPOUNDS AS CDK9 INHIBITORS AND THEIR USES | Novartis AG (CH) | 2013-12-04 | — | — | EP | disclosed |
| US-20130303507-A1 | SUBSTITUTED HETERO-BIARYL COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2013-11-14 | — | — | US | disclosed |
| US-20130172354-A1 | HETEROARYL COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2013-07-04 | — | — | US | disclosed |
| US-8415381-B2 | Heteroaryl compounds and their uses | NOVARTIS AG (CH) | 2013-04-09 | — | — | US | disclosed |
| WO-2012101065-A2 | PYRIMIDINE BIARYL AMINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| WO-2012101063-A1 | N-ACYL PYRIDINE BIARYL COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| WO-2012101066-A1 | PYRIDINE BIARYL AMINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| WO-2012101064-A1 | N-ACYL PYRIMIDINE BIARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| WO-2012101062-A1 | SUBSTITUTED BI-HETEROARYL COMPOUNDS AS CDK9 INHIBITORS AND THEIR USES | NOVARTIS AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| EP-2473499-A1 | BIPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2012-07-11 | — | — | EP | disclosed |
| EP-2459535-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS PROTEIN KINASE MODULATORS | Novartis AG (CH) | 2012-06-06 | — | — | EP | disclosed |
| US-20110130380-A1 | Heteroaryl Kinase Inhibitors | NOVARTIS AG (CH) | 2011-06-02 | — | — | US | disclosed |
| US-20110130380-A1 | Heteroaryl Kinase Inhibitors | NOVARTIS AG (CH) | 2011-06-02 | — | — | US | disclosed |
| US-20110130380-A1 | Heteroaryl Kinase Inhibitors | NOVARTIS AG (CH) | 2011-06-02 | — | — | US | disclosed |
| WO-2011026911-A1 | BIPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2011-03-10 | — | — | WO | disclosed |
| US-20110028492-A1 | Heteroaryl Compounds and Their Uses | NOVARTIS AG (CH) | 2011-02-03 | — | — | US | disclosed |
| WO-2011012661-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS PROTEIN KINASE MODULATORS | NOVARTIS AG (CH) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172354-A1 | HETEROARYL COMPOUNDS AND THEIR USES | CDK9, CDK19, CDK3 | GRM4 2195/4885ALDH1A1 2639/4885KDM4E 1459/4885 |
| US-20140288076-A1 | HETEROARYL COMPOUNDS AND THEIR USES | CDK9, CDK19, CDK3 | GRM4 2195/4885ALDH1A1 2639/4885KDM4E 1459/4885 |
| US-20110028492-A1 | Heteroaryl Compounds and Their Uses | CDK9, CDK19, CDK3 | GRM4 2195/4885ALDH1A1 2639/4885KDM4E 1459/4885 |
| US-20130303507-A1 | SUBSTITUTED HETERO-BIARYL COMPOUNDS AND THEIR USES | CDK9, CDK19, CDK3 | GRM4 3202/4885ALDH1A1 2220/4885KDM4E 1438/4885 |
| US-20110130380-A1 | Heteroaryl Kinase Inhibitors | CDK2, CDK1, CDKL1 | GRM4 4036/4885ALDH1A1 1763/4885KDM4E 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.